NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market Wednesday that its fourth-quarter revenues increased 32 percent to $1.1 million from $868,000, beating the consensus Wall Street estimate for revenues of $900,000.

The firm's product sales were $1 million for the three months ended Dec. 31, 2012, compared to $755,000 for the fourth quarter of 2011. License revenues were flat year over year at $113,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.